Oncolytics Biotech Aktie [WKN DE: A2JMW5 / ISIN: CA6823108759]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Oncolytics Biotech Inc Registered Shs

05.04.21		Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid... (PR Newswire)
05.04.21		Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid... (PR Newswire)
10.03.21		Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting (PR Newswire)
10.03.21		Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting (PR Newswire)
10.03.21		Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting (PR Newswire)
05.03.21		Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights (PR Newswire)
05.03.21		Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights (PR Newswire)
05.03.21		Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights (PR Newswire)
26.02.21		Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights (PR Newswire)
26.02.21		Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights (PR Newswire)
26.02.21		Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights (PR Newswire)
23.02.21		Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors (PR Newswire)
23.02.21		Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors (PR Newswire)
23.02.21		Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors (PR Newswire)
09.12.20		Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
09.12.20		Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
09.12.20		Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
19.11.20		Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
19.11.20		Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
19.11.20		Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
17.11.20		Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
17.11.20		Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
17.11.20		Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
11.11.20		Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results (PR Newswire)
11.11.20		Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results (PR Newswire)
11.11.20		Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results (PR Newswire)
09.11.20		Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
27.10.20		Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor (PR Newswire)
27.10.20		Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor (PR Newswire)
27.10.20		Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor (PR Newswire)
07.10.20		Oncolytics Biotech® to Participate in BIO Investor Forum Digital (PR Newswire)
07.10.20		Oncolytics Biotech® to Participate in BIO Investor Forum Digital (PR Newswire)
07.10.20		Oncolytics Biotech® to Participate in BIO Investor Forum Digital (PR Newswire)
29.05.20		At The ASCO: ONCY, IMV, CRDF, GILD, TAK… (RTTNews)
09.01.20		Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma (PR Newswire)
09.01.20		Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma (PR Newswire)
09.01.20		Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma (PR Newswire)
27.12.19		Oncolytics Biotech (ONCY) Hits New 52-week High, What's The Buzz? (RTTNews)
18.12.19		Top Gainers: VIE To Face FDA In June, NLTX Up 65% In Dec., Be AWARE Of ONCY (RTTNews)
03.10.19		Healthcare Stocks That Plunged To New Lows (SVRA, ONCY, MTFB…) (RTTNews)
06.08.19		5 Top Losers In Healthcare Sector (GLYC, LOGC, KZR…) (RTTNews)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Rosenbauer erwartet kein Problem bei Kapitalerhöhung wegen KTM-Pleite - Rosenbauer-Aktie fester

Pierer Mobility-Aktie bricht ein: KTM steht vor Insolvenz

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	30.11.2024 06:18
Kaufwert:	EUR
	Hinzufügen Speichern